About Erlin-1
Erlin-1 (ERLIN1) is a protein
from Homo sapiens identified by UniProt accession
O75477, 348 residues long.
MolForge cross-references it against 0 known binders and
80 disease associations.
Target properties
| Protein name | Erlin-1 |
|---|
| UniProt accession | O75477 |
|---|
| Gene | ERLIN1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 348 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (80)
Diseases linked to this target (Open Targets).
- Autosomal recessive spastic paraplegia type 62 · score 0.70
- hereditary spastic paraplegia 62 · score 0.67
- hereditary spastic paraplegia · score 0.57
- cystic fibrosis · score 0.46
- sex hormone-binding globulin measurement · score 0.39
- serum alanine aminotransferase measurement · score 0.38
- cognitive function measurement · score 0.35
- aspartate aminotransferase measurement · score 0.35
- high density lipoprotein cholesterol measurement · score 0.35
- juvenile amyotrophic lateral sclerosis · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75477-F1 | alphafold | PREDICTED | 85.19 | — |
Amino-acid sequence (348 residues)
MNMTQARVLV AAVVGLVAVL LYASIHKIEE GHLAVYYRGG ALLTSPSGPG YHIMLPFITT FRSVQTTLQT DEVKNVPCGT SGGVMIYIDR IEVVNMLAPY AVFDIVRNYT ADYDKTLIFN KIHHELNQFC SAHTLQEVYI ELFDQIDENL KQALQKDLNL MAPGLTIQAV RVTKPKIPEA IRRNFELMEA EKTKLLIAAQ KQKVVEKEAE TERKKAVIEA EKIAQVAKIR FQQKVMEKET EKRISEIEDA AFLAREKAKA DAEYYAAHKY ATSNKHKLTP EYLELKKYQA IASNSKIYFG SNIPNMFVDS SCALKYSDIR TGRESSLPSK EALEPSGENV IQNKESTG
Explore Erlin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets